Across TCGA pan-cancer cohorts, SKIV2L Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SKIV2L data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher SKIV2L Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated SKIV2L expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.
SKCM, THYM, and COAD are the cancer types where SKIV2L Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.